A Phase 3 interventional study of FTY720 and Placebo in Primary Progressive Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Terminated at 157 sites in 18 countries. Open to participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-06-14.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis — 1 open to participants now, 2 under way, 1 of them phase 3. Multiple Sclerosis, Chronic Progressive · Novartis.
Among the 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis, this one is the only one that started in 2008, is one of 3 in phase 3, and was the 1st registered.
245 studies on the registry are indexed under Multiple Sclerosis, Chronic Progressive; 54 are open to participants now.
Browse Multiple Sclerosis, Chronic Progressive studies →1 of the 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–65
By country, each count listing its studies:
Of the 39 Multiple Sclerosis, Chronic Progressive studies recruiting now, 7 (18%) set no upper age limit and 26 (67%) stop at 75 or younger; none take children under 18; 6 take healthy volunteers.
This study: 25 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 970 is above the median of 54 across 190 interventional studies indexed under Multiple Sclerosis, Chronic Progressive.
Median enrollment 627 across the 6 interventional studies, 210 across the 9 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Multiple Sclerosis, Chronic Progressive by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate whether FTY720 is effective in delaying MS disability progression compared to placebo in patients with PPMS. This was an open-label, single-arm extension study to a double-blind, randomized multicenter, placebo-controlled, parallel-group core study. The core study completed and eligible patients enrolled into the extension study at the next scheduled or unscheduled core study visit. All patients, regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension study. The extension study was terminated early after the results of the core study became available showing that the study did not meet its primary endpoint which was defined as confirmed disability progression in this population
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General
females of must:
Primary Progressive Multiple sclerosis.
disability status at Screening
Extension study Inclusion criteria
Exclusion Criteria:
PPMS specific:
Cardiovascular conditions:
Pulmonary:
Hepatic:
Other:
Drugs requiring :
3 months:
INF-beta
6 months:
Extension study Exclusion criteria
-Patients were not eligible for enrollment in the extension study if they had any of the following key exclusion criteria at the extension study Baseline visit: active chronic immune system disease other than MS (or stable disease treated with immune therapy); known immunodeficiency syndrome; active infection; uncontrolled diabetes mellitus; macularedema; treatment with Class Ia or III antiarrhythmic drugs; any of the specified cardiac, pulmonary, or hepatic conditions; or any medically unstable condition
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment
Drug: FTY720
Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization
Drug: Placebo
Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009
Drug: FTY720
Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
Matching placebo capsules were administered orally once daily
Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint
3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25' TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25' TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.
Time frame: up to 36 months after the last patient was randomized
Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)
The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)
Time frame: up to 36 months after the last patient was randomized
Percent Change From Baseline in Brain Volume at Month 36
The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.
Time frame: Baseline to month 36
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.
The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis
Time frame: up to 36 months after the last patient was randomized
Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.
The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis
Time frame: up to 36 months after the last patient was randomized
Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36
Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis
Time frame: Baseline to 36 months
Number of Gd-enhancing Lesions at Month 36
Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis
Time frame: Baseline to 36 months
Percent Change in Total T2 Lesion Volume From Baseline to Month 36
Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis
Time frame: Baseline to month 36
Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)
The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score
Time frame: Baseline, 36 months
Change From Baseline in PRIMUS-Activities
The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).
Time frame: Baseline, 36 months
Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score
Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).
Time frame: Baseline, 36 months
Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score)
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
Time frame: Baseline, 36 months
Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)
The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42\*100).
Time frame: Baseline, 36 months
Blood Concentrations of Fingolimod and Fingolimod-phosphate
Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate. Venous blood samples were collected for the analysis.
Time frame: Month 3 up to 36 months
Change in MSFC Z-score and Subscale Scores From Baseline to Month 36
The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.
Time frame: Baseline to Month 36
Patients were randomized equally to receive either fingolimod or placebo. Patients initially randomized to fingolimod 1.25 mg/day or matching placebo groups switched in a blinded manner to fingolimod 0.5 mg/day or continued on placebo after amendment in Nov. 2009. Patients were randomized to receive either fingolimod 0.5 mg/day or placebo..
| Milestone | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo to -FTY 0.5 mg |
|---|---|---|---|
| Started | 147 | 336 | 487 |
| Safety set (saf) | 0 | 336 | 487 |
| Full analysis set (fas) | 0 | 336 | 487 |
| Pharmacokinetic analysis set | 102 | 249 | 0 |
| Post protocol amendment 5 switch | 0 | 121 | 0 |
| Completed | 79 | 220 | 317 |
| Not completed | 68 | 116 | 170 |
| Withdrew: Lack of efficacy | 11 | 23 | 64 |
| Withdrew: Physician decision | 1 | 0 | 2 |
| Withdrew: Death | 2 | 1 | 2 |
| Withdrew: Lost to follow-up | 1 | 3 | 3 |
| Withdrew: Administrative | 2 | 2 | 6 |
| Withdrew: Abnormal test procedure result | 4 | 3 | 5 |
| Withdrew: Protocol violation | 4 | 5 | 8 |
| Withdrew: Abnormal lab values | 6 | 19 | 5 |
| Withdrew: Adverse event | 25 | 28 | 29 |
| Withdrew: Withdrawal by subject | 12 | 32 | 46 |
| Milestone | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo to -FTY 0.5 mg |
|---|---|---|---|
| Started | 74 | 196 | 301 |
| Completed | 0 | 0 | 0 |
| Not completed | 74 | 196 | 301 |
| Withdrew: Admin problems: terminated # patients | 69 | 189 | 277 |
| Withdrew: Abnormal test procedure | 0 | 0 | 1 |
| Withdrew: Abnormal lab values | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 4 |
| Withdrew: Withdrawal by subject | 4 | 5 | 3 |
| Withdrew: Adverse event | 1 | 1 | 15 |
3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25' TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25' TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.
| Percentage of Participants | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint | 77.2 (71.87 to 82.51) | 80.3 (73.31 to 87.25) |
The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)
| Percentage of Participants | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS) | 54.3 (47.16 to 61.45) | 58.7 (53.30 to 64.18) |
The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.
| Percent Change | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Percent Change From Baseline in Brain Volume at Month 36 | -1.49 (-1.64 to -1.35) | -1.53 (-1.65 to -1.41) |
The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis
| Percentge of Participants | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT. | 25.0 | 24.9 |
The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis
| Percentage of Participants | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT. | 54.8 | 56.7 |
Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis
| T2 Lesions per year | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36 | 0.13 (0.10 to 0.18) | 0.50 (0.40 to 0.61) |
Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis
| Gd-enhanced lesions per patient per scan | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Number of Gd-enhancing Lesions at Month 36 | 0.05 (0.02 to 0.09) | 0.21 (0.15 to 0.30) |
Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis
| Percent Change | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|
| Percent Change in Total T2 Lesion Volume From Baseline to Month 36 | -9.2 ± 30.55 | 8.9 ± 44.13 |
The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score
| Score on a scale | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score) | 0.2424 ± 4.18444 | 0.5921 ± 4.77704 | 0.9597 ± 4.38578 |
The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).
| Score on a scale | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in PRIMUS-Activities | 3.5504 ± 7.05241 | 2.6324 ± 6.22256 | 2.8830 ± 6.76499 |
Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).
| Score on a scale | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score | 1.3197 ± 12.44042 | 2.8451 ± 14.04769 | 3.1394 ± 12.20929 |
EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.
| Score on a scale | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score) | -0.0332 ± 0.19420 | -0.0475 ± 0.26099 | -0.0539 ± 0.22383 |
The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42\*100).
| Score on a scale | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score) | 6.4444 ± 23.81568 | 5.5616 ± 24.59030 | 9.5899 ± 23.98316 |
Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate. Venous blood samples were collected for the analysis.
| ng/ml | FTY720 1.25 mg to 0.5 mg | FTY720 1.25mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg |
|---|---|---|---|
| Month 3 Fingolimod (n=64, 179) | 6.04 ± 3.11 | NA ± NA | 2.58 ± 1.34 |
| Month 12 Fingolimod (n=23, 161) | 6.24 ± 2.21 | 2.87 ± 1.70 | 2.55 ± 1.37 |
| Month 18 Fingolimod (n=71,155) | NA ± NA | 2.44 ± 1.15 | 2.59 ± 1.44 |
| Month 24 Fingolimod (n=67, 160) | NA ± NA | 2.41 ± 1.30 | 2.64 ± 1.50 |
| Month 30 Fingolimod (n=62, 158) | NA ± NA | 2.52 ± 1.28 | 2.60 ± 1.33 |
| Month 36 Fingolimod (n=55, 118) | NA ± NA | 2.44 ± 1.08 | 2.63 ± 1.38 |
| End of treatment Fingolimod (n=32, 115) | NA ± NA | 2.02 ± 1.10 | 2.57 ± 1.51 |
| Month 3 Fingolimod-Phosphate (n=64, 179) | 3.20 ± 1.73 | NA ± NA | 1.40 ± 0.747 |
| Month 12 Fingolimod-Phosphate (n=23, 161) | 3.21 ± 1.16 | 1.54 ± 0.871 | 1.43 ± 0.805 |
| Month 18 Fingolimod-Phosphate (n=71,155) | NA ± NA | 1.34 ± 0.630 | 1.41 ± 0.758 |
| Month 24 Fingolimod-Phosphate (n=67, 160) | NA ± NA | 1.35 ± 0.765 | 1.44 ± 0.790 |
| Month 30 Fingolimod-Phosphate (n=62, 158) | NA ± NA | 1.32 ± 0.676 | 1.48 ± 0.759 |
| Month 36 Fingolimod-Phosphate (n=55, 118) | NA ± NA | 1.32 ± 0.591 | 1.51 ± 0.765 |
| End of treatment Fingolimod-Phosphate (n=32, 115 | NA ± NA | 1.19 ± 0.618 | 1.50 ± 0.900 |
The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.
| Z-scores | FTY720 0.5 mg | Placebo |
|---|---|---|
| Change in MSFC Z-score and Subscale Scores From Baseline to Month 36 | -0.189 ± 0.6980 | -0.212 ± 0.8468 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Core: FTY720 1.25 mg | — | 38/147 (25.9%) | 132/147 (89.8%) |
| Core: FTY720 0.5 mg | — | 84/336 (25%) | 278/336 (82.7%) |
| Core: Placebo | — | 117/487 (24%) | 406/487 (83.4%) |
| Extension: FTY1.25-0.5 | — | 7/74 (9.5%) | 43/74 (58.1%) |
| Extension: FTY0.5-0.5 | — | 10/196 (5.1%) | 70/196 (35.7%) |
| Extension: Placebo-FTY0.5 | — | 37/301 (12.3%) | 138/301 (45.8%) |
| Event | Core: FTY720 1.25 mg | Core: FTY720 0.5 mg | Core: Placebo | Extension: FTY1.25-0.5 | Extension: FTY0.5-0.5 | Extension: Placebo-FTY0.5 |
|---|---|---|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/147 | 11/336 | 9/487 | 1/74 | 2/196 | 1/301 |
| Urinary tract infectionInfections and infestations | 2/147 | 8/336 | 12/487 | 1/74 | 0/196 | 4/301 |
| FallInjury, poisoning and procedural complications | 3/147 | 1/336 | 3/487 | 0/74 | 0/196 | 0/301 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/147 | 6/336 | 1/487 | 0/74 | 0/196 | 1/301 |
| BradycardiaCardiac disorders | 2/147 | 2/336 | 0/487 | 0/74 | 0/196 | 0/301 |
| PneumoniaInfections and infestations | 2/147 | 4/336 | 2/487 | 1/74 | 0/196 | 1/301 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/147 | 1/336 | 0/487 | 1/74 | 0/196 | 0/301 |
| Multiple sclerosisNervous system disorders | 2/147 | 3/336 | 5/487 | 0/74 | 0/196 | 2/301 |
| Uhthoff's phenomenonNervous system disorders | 2/147 | 0/336 | 0/487 | 0/74 | 0/196 | 0/301 |
| Bursitis infectiveInfections and infestations | 0/147 | 0/336 | 0/487 | 1/74 | 0/196 | 0/301 |
| Event | Core: FTY720 1.25 mg | Core: FTY720 0.5 mg | Core: Placebo | Extension: FTY1.25-0.5 | Extension: FTY0.5-0.5 | Extension: Placebo-FTY0.5 |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 40/147 | 78/336 | 135/487 | 9/74 | 10/196 | 23/301 |
| FallInjury, poisoning and procedural complications | 31/147 | 47/336 | 91/487 | 6/74 | 5/196 | 13/301 |
| HeadacheNervous system disorders | 28/147 | 56/336 | 77/487 | 3/74 | 3/196 | 13/301 |
| HypertensionVascular disorders | 23/147 | 43/336 | 28/487 | 2/74 | 5/196 | 18/301 |
| Urinary tract infectionInfections and infestations | 21/147 | 47/336 | 75/487 | 4/74 | 11/196 | 25/301 |
| Back painMusculoskeletal and connective tissue disorders | 16/147 | 36/336 | 75/487 | 5/74 | 5/196 | 10/301 |
| Upper respiratory tract infectionInfections and infestations | 21/147 | 37/336 | 57/487 | 6/74 | 6/196 | 14/301 |
| Melanocytic naevusNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 21/147 | 16/336 | 31/487 | 4/74 | 3/196 | 9/301 |
| Gamma-glutamyltransferase increasedInvestigations | 19/147 | 31/336 | 3/487 | 0/74 | 3/196 | 5/301 |
| Alanine aminotransferase increasedInvestigations | 17/147 | 39/336 | 7/487 | 0/74 | 1/196 | 6/301 |
| Age, Continuous(years) | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 47.8 ± 8.47 | 48.5 ± 8.59 | 48.5 ± 8.31 | 48.5 ± 8.42 |
| Age, Customized(Particpants) | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| <=30 | 3 | 6 | 4 | 13 |
| 31 to 40 | 22 | 60 | 90 | 172 |
| 41 to 50 | 68 | 127 | 194 | 389 |
| >50 | 54 | 143 | 199 | 396 |
| Sex: Female, Male(Participants) | FTY720 1.25 mg to 0.5 mg | FTY720 0.5 mg to 0.5 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 71 | 163 | 235 | 469 |
| Male | 76 | 173 | 252 | 501 |
Showing the first 100 of 157 sites across 18 countries. Choose a country and city above to see the rest.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2008 to primary completion in Jun 2015, 82 months.
Results were first posted in Jun 2017, 1 year 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod
Multiple Sclerosis, Chronic Progressive →